<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01913431</url>
  </required_header>
  <id_info>
    <org_study_id>ETV_HB_IV</org_study_id>
    <nct_id>NCT01913431</nct_id>
  </id_info>
  <brief_title>Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B</brief_title>
  <official_title>A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Group Study to Demonstrate the Comparison and Evaluation of Baracle Tab.® and Baraclude Tab.® for HBeAG Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double blind, active-controlled, randomized, parallel group study to
      demonstrate the anti-viral activity and safety of Baracle Tab. and Baraclude Tab. for
      patients with HBeAg Chronic Hepatitis B. The subject will receive two tablets daily for 48
      days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2013</start_date>
  <completion_date type="Actual">November 6, 2015</completion_date>
  <primary_completion_date type="Actual">November 6, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Difference between HBV DNA level(log10) and the base line of HBV DNA level(log10)</measure>
    <time_frame>52 weeks</time_frame>
    <description>measured at 24th week of the administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the percentage of participants who have less than 300 copies/ml of HBV DNA (undetectable titre)</measure>
    <time_frame>52 weeks</time_frame>
    <description>measured at 24th/48th week of the administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of participants with normalization of serum alanine aminotransferase (less than 1.0 times the upper limit of normal)</measure>
    <time_frame>52 weeks</time_frame>
    <description>measured at 24th/48th week of the administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the percentage of participants who have lost HBeAg</measure>
    <time_frame>52 weeks</time_frame>
    <description>HBeAg of the participants was found positive at their screening visit. Also, the measurement performs 24th/48th week of the administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>HBeAg-Positive Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Baracle Tab.®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(It can be also placebo) dosage: 2 tablets daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baraclude Tab.®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(It can be also placebo) dosage: 2 tablets daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baracle Tab.®</intervention_name>
    <arm_group_label>Baracle Tab.®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baraclude Tab.®</intervention_name>
    <arm_group_label>Baraclude Tab.®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with HbeAg Chronic Hepatitis B for at least six months starting from the
             Screening visit

          -  Subjects with HBsAg-Positive diagnosed at the screening visit

          -  Subjects with HBeAg-Positive or HBeAg-negative diagnosed at the screening visit

          -  For those who were diagnosed HBeAg-Positive, HBV DNA level should be equal or more
             than 1x10^5 copies/ml

          -  For those who were diagnosed HBeAg-Negative, HBV DNA level should be equal or more
             than 1x10^5 copies/ml

          -  Subjects who were NOT administrated any anti-viral agents including interferon or
             pegylated interferon

        Exclusion Criteria:

          -  Subjects with HCV, HDV or HIV

          -  Subjects with decompensated liver disease who have more than 2.5mg/dl of total
             bilirubin, longer than 3 seconds of prothrombin time, less than 30g/l of serum albumin

          -  With medical history of hemorrhage, hepatic encephalopathy, or dyshepatia due to
             ascites, jaundice, varicose vein

          -  Less than 50ml/min of creatinine clearance diagnosed at the screening visit

          -  More than 50 ng/ml of alpha-fetoprotein at the screening visit

          -  Involved in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han Chu Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Si Hyun Bae, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ju Hyun Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University of Medicine and Science Gil Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Seok Hwang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>So Young Kwon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Won Young Tak</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunpook National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Eun Yeon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korae University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Young Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joon Hyouk Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung Hwan Yoon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Hoon Ahn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neung Hwa Park, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulsan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youn Jae Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>In Hee Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byung Seok Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2013</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

